Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 24/5/2020
SIETES contiene 93008 citas

 
 
<< anterior 21 a 40 de 729 siguiente >>
Presentar resultados
Seleccionar todas
21.Enlace a cita original Cita con resumen
Avorn J. The psychology of clinical decision making — Implications for medication use. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102556]
22. Cita con resumen
23.Enlace a cita original Cita con resumen
Hernández-Aguado I, Chilet-Rosell E. Pathways of undue influence in health policy-making: a main actor's perspective. J Epidemiol Community Health 2018;72:154-9. [Ref.ID 102446]
24. Cita con resumen
Greene JA, Loscalzo J. Putting the patient back together — Social medicine, network medicine, and the limits of reductionism. N Engl J Med 2017;377:2493-9. [Ref.ID 102185]
25. Cita con resumen
Iacobucci G. NHS to stop funding homeopathy and some drugs in targeted savings drive. BMJ 2017;358:j3560. [Ref.ID 102013]
26. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
27. Cita con resumen
Zaman MJ. Cost saving is nothing to be proud of. BMJ 2017;358:j3428. [Ref.ID 101978]
28. Cita con resumen
Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S, Wu T, Schoen-baum M, Hutchins D, Brennan T, Loewen-stein G. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 2017;317:1785-95. [Ref.ID 101559]
29. Cita con resumen
Anónimo. NICE endorses bosutinib for treatment of myeloid leukemia. DIA Daily 2016:3. [Ref.ID 100484]
31. Cita con resumen
32. Cita con resumen
Ghinea N, Lipworth W, Kerridge I. Propaganda or the cost of innovation? Challenging the high price of new drugs. BMJ 2016;352:i1284. [Ref.ID 100333]
33. Cita con resumen
Anónimo. Prescription charges for 2016. Prescribing Advice for GPs 2016:6 de mayo. [Ref.ID 100330]
34.Enlace a cita original Cita con resumen
Vigario A. Pfizer despide a 30 altos cargos en España por incumplir el código ético. El Economista 2015:1. [Ref.ID 100040]
35. Cita con resumen
Rubin R. GAO reports costs of new Medicare Part B drugs in 2013. JAMA 2016;315:122. [Ref.ID 99972]
36. Cita con resumen
Arie S. The device industry and payments to doctors. BMJ 2015;351:h6182. [Ref.ID 99754]
37. Cita con resumen
Hawkes N. Five cancer drugs back on NHS list after deals with drug companies. BMJ 2015;351:h5985. [Ref.ID 99684]
38. Cita con resumen
McCarthy M. US Senate committee launches investigation into drug pricing. BMJ 2015;351:h5989. [Ref.ID 99683]
39. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
40. Cita con resumen
Seleccionar todas
 
<< anterior 21 a 40 de 729 siguiente >>